Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA
- PMID: 12234166
- DOI: 10.1053/bbmt.2002.v8.pm12234166
Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA
Abstract
Cytotoxic T-cells (CTLs) specific for the hematopoietic system-restricted minor histocompatibility antigen (mHag) HA-1 efficiently lyse HA-1-positive leukemic cells without affecting nonhematopoietic cells. HA-1-specific CTLs are thus potential tools for adoptive immunotherapy of relapsed leukemia after HLA-matched-HA-1-mismatched stem cell transplantation (SCT). In vitro generation of HA-1-specific CTLs from SC donors is possible using dendritic cells (DCs) pulsed with synthetic HA-1 peptide as stimulator cells. However, this approach requires at least 6 weeks of in vitro culturing under GMP (good manufacturing practice) conditions. Our data show that in vitro induction of HA-1-specific CTLs is more rapid with the use of DCs that are retrovirally transduced with the HA-1 complementary DNA. Retrovirally transduced DCs showed functional and long-term stable expression of the HA-1 CTL epitope in primary CTL cultures. In 4 SC donors, HA-1-transduced DCs induced HA-1-specific CTLs in 14 to 21 days. The in vitro-generated CTL lines contained 6% to 9% T-cells that stained brightly with tetrameric HLA-A2/HA-1 peptide complexes (HA-1(A2) tetramer) and showed significant lysis of HA-1+ leukemic cells. The CTL induction procedure using peptide-pulsed DCs was less effective and required 28 to 35 days of T-cell culture. Thus, sustained presentation of mHag HA-1 by retrovirally transduced DCs facilitates the in vitro induction of HA-1-specific CTLs.
Similar articles
-
Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.Blood. 2002 Jul 15;100(2):547-52. doi: 10.1182/blood-2002-01-0024. Blood. 2002. PMID: 12091347
-
Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.Blood. 1999 Apr 1;93(7):2336-41. Blood. 1999. PMID: 10090944
-
HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand.Hematol J. 2000;1(6):403-10. doi: 10.1038/sj.thj.6200065. Hematol J. 2000. PMID: 11920221
-
The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.J Immunol. 2001 Aug 1;167(3):1712-9. doi: 10.4049/jimmunol.167.3.1712. J Immunol. 2001. PMID: 11466395
-
Signal 0 for guided priming of CTLs: NKT cells do it too.Nat Immunol. 2010 Apr;11(4):284-6. doi: 10.1038/ni0410-284. Nat Immunol. 2010. PMID: 20300136 Review. No abstract available.
Cited by
-
Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.J Clin Invest. 2003 Dec;112(12):1880-6. doi: 10.1172/JCI19427. J Clin Invest. 2003. PMID: 14679183 Free PMC article.
-
Potential clinical applications for human pluripotent stem cell-derived blood components.Stem Cells Int. 2011 Mar 8;2011:273076. doi: 10.4061/2011/273076. Stem Cells Int. 2011. PMID: 21437192 Free PMC article.
-
Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.Bone Marrow Transplant. 2016 Feb;51(2):163-71. doi: 10.1038/bmt.2015.256. Epub 2015 Oct 26. Bone Marrow Transplant. 2016. PMID: 26501766 Review.
-
Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study.Haematologica. 2012 Aug;97(8):1205-8. doi: 10.3324/haematol.2011.053371. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511490 Free PMC article.
-
Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.Int J Hematol. 2003 Oct;78(3):208-12. doi: 10.1007/BF02983796. Int J Hematol. 2003. PMID: 14604278 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials